Polyphyllin VII protects from breast cancer-induced osteolysis by suppressing osteoclastogenesis via c-Fos/NFATc1...

Area of Science:

• Oncology
• Pharmacology
• Bone Biology

Background:

• Bone metastasis is a common complication of advanced breast cancer, leading to poor survival rates.
• Targeting osteoclasts is a therapeutic strategy for managing skeletal-related events in breast cancer.
• Polyphyllin VII (PP7), a saponin from Paris polyphylla, possesses anti-inflammatory and anti-cancer properties.

Purpose of the Study:

• To investigate the efficacy of Polyphyllin VII (PP7) in mitigating breast cancer-induced bone destruction.
• To elucidate the underlying mechanisms by which PP7 affects bone metastasis and osteoclastogenesis.

Main Methods:

• In vivo studies using mice with breast cancer MDA-MB-231 cell-induced osteolysis.
• In vitro experiments assessing PP7's effect on osteoclast formation and bone resorption induced by MDA-MB-231 conditioned medium (MDA-MB-231 CM).
• Analysis of signaling pathways (c-Fos, NFATc1) and gene expression (Oscar, Atp6v0d2, Mmp9, β3 integrin) in osteoclastogenesis.

Main Results:

• Intraperitoneal administration of PP7 (1 mg/kg) significantly reduced osteolysis in mice.
• PP7 inhibited MDA-MB-231 CM-induced osteoclast formation and bone resorption in vitro.
• PP7 downregulated c-Fos and NFATc1 signaling pathways, decreasing osteoclast-related gene expression.
• PP7 treatment promoted osteoblast formation.

Conclusions:

• Polyphyllin VII demonstrates significant therapeutic potential in preventing and treating bone destruction associated with breast cancer bone metastasis.
• PP7 acts by inhibiting osteoclastogenesis and promoting osteoblast formation, offering a novel strategy for managing skeletal complications.